Holder plans sale of 100,000 CLYM shares

The holder of CLYM common stock has filed a notice of proposed sale of 100,000 shares through Morgan Stanley Smith Barney on or after February 12, 2026 on NASDAQ, with an aggregate market value of $556,000.

Rhea-AI Filing Summary

The holder of CLYM common stock has filed a notice of proposed sale of 100,000 shares through Morgan Stanley Smith Barney on or after February 12, 2026 on NASDAQ, with an aggregate market value of $556,000. The filing states that 68,184,435 shares of this class were outstanding at the time of the notice.

The shares to be sold were acquired from the issuer as restricted stock units on January 1, 2025 (50,188 shares) and as founders’ shares on November 15, 2023 (49,812 shares). The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the CLYM Form 144 filing disclose about planned share sales?

The filing discloses a planned sale of 100,000 CLYM common shares on NASDAQ with an aggregate market value of $556,000. It is a notice of intent to sell, not confirmation that the sale has already occurred.

How many CLYM shares are outstanding according to this Form 144?

The notice states that 68,184,435 CLYM common shares were outstanding when the form was prepared. This figure provides context for the planned 100,000-share sale, showing it is a small fraction of the total outstanding shares.

When were the CLYM shares being sold under Form 144 originally acquired?

The shares were acquired from the issuer as restricted stock units on January 1, 2025 (50,188 shares) and as founders’ shares on November 15, 2023 (49,812 shares). Both acquisitions are listed as non-cash, with the nature of payment marked N/A.

Which broker is handling the planned CLYM share sale in this Form 144?

The planned sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The shares are expected to be sold on the NASDAQ market.

What representation does the seller make in the CLYM Form 144 filing?

The seller represents that they do not know of any material adverse information about the issuer’s current or future operations that has not been publicly disclosed. This representation is required when filing a notice for a proposed Rule 144 sale.

Does the CLYM Form 144 show any other sales in the past three months?

The section requesting information on securities sold during the past three months is included, but no specific past transactions are detailed in the provided excerpt. The focus of the disclosed data is the upcoming planned sale of 100,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:28 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002027962
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CLIMB BIO, INC.
SEC File Number	001-40708
Address of Issuer	20 William Street Wellesley Hills MASSACHUSETTS 02481
Phone	866-857-2596
Name of Person for Whose Account the Securities are To Be Sold	STEPHEN THOMAS
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	100000	556000.00	68184435	02/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/01/2025	Restricted Stock Units	Issuer			50188	01/01/2025	N/A
Common	11/15/2023	Founders Shares	Issuer			49812	11/15/2023	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	10/14/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Stephen Basil Thomas
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)